Long-term final results within people along with superior and/or metastatic non-small mobile or portable cancer of the lung which completed 2 years regarding immune system checkpoint inhibitors or perhaps reached a durable reaction following discontinuation without having disease further advancement: Multicenter, real-world files (KCSG LU20-11).